Related Experiment Video
Updated: Feb 28, 2026
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Actinolactomycin from Streptomyces sp. CB00271: Isolation, Identification, and Potent Anti-Triple-Negative Breast
Bang Gong1,2, Jian Pan1,2, Jun Zhang1
1College of Pharmacy, Hunan Vocational College of Science and Technology, Changsha 410004, China.
Abstract:
Triple-negative breast cancer (TNBC) is a highly aggressive subtype with limited targeted therapies, underscoring an urgent need for novel agents. The soil-derived Streptomyces sp. CB00271, isolated from a biodiversity hotspot, was investigated for its bioactive metabolites. Bioassay-guided isolation led to the identification of actinolactomycin (1), alongside daidzein (2) and genistein (3). Remarkably, actinolactomycin (1) exhibited potent cytotoxicity against TNBC models, with IC50 values of 0.72 ± 0.12 μM (MDA-MB-231) and 0.15 ± 0.02 μM (4T1), demonstrating approximately 9-fold and 31-fold greater potency than cisplatin, respectively, and suggesting action through targeted pathway inhibition. This study constitutes the first report to systematically highlight the exceptional anti-TNBC potential of this rare natural product, establishing it as a promising lead compound against this challenging subtype. Furthermore, Streptomyces sp. CB00271 is identified as a valuable and scarce microbial resource for actinolactomycin, providing a new avenue to address its supply limitation and facilitate future development.
Insights
A novel compound, actinolactomycin, from Streptomyces bacteria shows potent activity against triple-negative breast cancer (TNBC). This natural product offers a promising new therapeutic avenue for this aggressive cancer subtype.
Area of Science:
- Natural Product Chemistry
- Oncology
- Microbiology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapy options.
- There is an urgent need for novel therapeutic agents to combat TNBC.
- Soil-derived microorganisms are a rich source of bioactive compounds.
Purpose of the Study:
- To investigate the bioactive metabolites of Streptomyces sp. CB00271 for novel anti-cancer agents.
- To evaluate the anti-cancer potential of isolated compounds against TNBC models.
- To establish Streptomyces sp. CB00271 as a valuable resource for actinolactomycin production.
Main Methods:
- Bioassay-guided isolation of metabolites from Streptomyces sp. CB00271.
- Cytotoxicity assays using TNBC cell lines (MDA-MB-231 and 4T1).
- Comparison of actinolactomycin's potency with cisplatin.
Main Results:
- Actinolactomycin (1) was isolated and identified.
- Actinolactomycin demonstrated potent cytotoxicity against TNBC models (IC50 values of 0.72 μM and 0.15 μM).
- Actinolactomycin showed significantly higher potency than cisplatin against TNBC cells.
Conclusions:
- Actinolactomycin is a promising lead compound for developing new treatments for triple-negative breast cancer.
- Streptomyces sp. CB00271 is a valuable microbial resource for producing actinolactomycin.
- Further research into actinolactomycin's mechanism of action and therapeutic development is warranted.
More Related Videos
09:08From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028
Published on: January 13, 2017
07:03Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
Published on: October 2, 2020
Related Concept Videos
01:30Bacterial Phylum Actinobacteria
01:15Drugs that Stabilize Microtubules